Effect of Moxifloxacin-Triple Therapy Versus Clarithromycin-Triple Therapy for the Eradication of Helicobacter Pylori Infections Regarding to Age and BMI.

Abstract

Helicobacter pylori (H. Pylori) is one of the most common infectious human pathogens, which infected morethan (50%) of the populations worldwide.H. pylori induce inflammation, which causes of upper gastrointestinal illnesses including dyspepsia, peptic ulcerdiseases, gastroesophageal reflux disease and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. It is important to use a greatly effective and better tolerated eradication regimen. In this study, fifty newly diagnosed adult patients with H. pylori infection were included, they were allocated into two groups with two different treatment regimens for H. pylori eradications; Group A (25 patients) received oral conventional clarithromycin-triple therapy for 14 days. Group B (25 patients) received oral moxifloxacin triple therapy for 14 days. The results reported in this study indicated a significant higher eradication rate of triple moxifloxacin regimen (80%) of patients with H. pylori infections compared to that of triple clarithromycin regimen (52%). In the present study, using different H.pylori eradication regimens for patients with different age groups demonstrated no statistically significant differences in eradication rate achieved (p< 0.05). The result of this study showed that triple moxifloxacin therapy produced a significant higher eradication rate than clarithromycin triple therapy among normal weight patients with H. pylori infection (100% and 50% respectively (p=0.032)), while there was no significance difference among overweight and obese patients (p< 0.05) between the two groups. The present study concluded that the administration of moxifloxacin triple regimen for H. pylori eradication, demonstrated eradication effectiveness was significantly higher compared to that of clarithromycin triple regimen